David A. Siegel Prelude Therapeutics Inc Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 70,200 shares of PRLD stock, worth $267,462. This represents 0.0% of its overall portfolio holdings.

Number of Shares

70,200

Previous 61,800 13.59%

Holding current value

$267,462

Previous $263,000 26.24%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.68 - $4.84 $22,512 - $40,656	8,400 Added 13.59%	70,200 $332,000
Q4 2023 Feb 14, 2024	BUY	$1.69 - $4.37 $51,883 - $134,159	30,700 Added 98.71%	61,800 $263,000
Q3 2023 Nov 14, 2023	SELL	$2.74 - $4.79 $43,018 - $75,203	-15,700 Reduced 33.55%	31,100 $96,000
Q2 2023 Aug 14, 2023	SELL	$4.45 - $8.12 $16,465 - $30,043	-3,700 Reduced 7.33%	46,800 $210,000
Q1 2023 May 15, 2023	SELL	$4.58 - $7.34 $113,584 - $182,032	-24,800 Reduced 32.93%	50,500 $287,000

Q4 2022 Feb 14, 2023	SELL	$4.61 - $8.5 $157,814 - $290,980	-34,233 Reduced 31.25%	75,300 $454,000
Q3 2022 Nov 14, 2022	SELL	$5.0 - $8.82 $630,835 - $1.11 Million	-126,167 Reduced 53.53%	109,533 $724,000
Q2 2022 Aug 15, 2022	BUY	$4.0 - $7.55 $436,800 - $824,460	109,200 Added 86.32%	235,700 $1.23 Million
Q1 2022 May 16, 2022	BUY	$6.9 - $13.22 $291,180 - $557,884	42,200 Added 50.06%	126,500 $873,000
Q4 2021 Feb 14, 2022	BUY	$11.89 - $31.74 $1 Million - $2.68 Million	84,300 New	84,300 $1.05 Million

Others Institutions Holding PRLD

# of Institutions

Shares Held

34.2M

Call Options Held

200

Put Options Held

View Full List

About Prelude Therapeutics Inc

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $139M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

More about PRLD

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account